Regulated Induced Proximity Targeting Chimeras (RIPTACs) represent a novel therapeutic modality designed to elicit a "Hold-and-Kill" mechanism by cross-linking a tumor-specific target with an essential effector protein (e.g., BRD4), leading to robust cell death. However, validating novel RIPTAC pairs requires rigorous multi-dimensional evaluation. Here, we present a systematic validation platform for new RIPTAC and TCIP pairs. Our strategy initiates with AI-driven (AIDD) structural predictions of ternary protein-protein interactions. At the protein level, biophysical and biochemical assays, including SPR and HTRF, are deployed to quantify binding kinetics and ternary cooperativity. Moving to the cellular context, we utilize NanoBRET, AlphaLISA, and rigorously controlled inducible expression systems to confirm target-dependent induced proximity in live cells. Functionally, extensive cell panel assays demonstrate a strong correlation between biomarker expression (e.g., ESR1 nTPM) and RIPTAC-mediated cytotoxicity, successfully overcoming resistance mechanisms seen with traditional degraders like Fulvestrant. Finally, transcriptomic and biomarker analyses elucidate the distinct mechanism of action, highlighting severe transcriptional stress and unique cell death pathways. Furthermore, we demonstrate the platform's versatility by expanding to novel targets, including p53-Y220C complexes. This integrated workflow streamlines the discovery, optimization, and mechanistic validation of next-generation induced-proximity therapeutics.
We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel:+86-10-67809840
Get a quote
Go top